Enliven Therapeutics Inc
Enliven Therapeutics Inc (ELVN) Option Chain
Enliven Therapeutics Inc trades at $46.53, up 0.26%, with an IV Rank of 12.70%. This is low versus the past year, and the company carries a market cap of $3,424M in the Biotechnology industry. On the Dec 18, 2026 chain, the at the money $45.00 strike shows calls at $2.15 / $5.70 and puts at $0.20 / $4.20, both carrying about $2.30 of extrinsic value. The call has a 44.25% probability of expiring out of the money, and the put has 55.75%. Volume is heaviest on the $55.00 calls, at 2 contracts, and the $45.00 puts, at 6, as of Nov 20, 2026.
Read more
Tracking the ELVN option chain helps you see every strike and expiry on Enliven Therapeutics Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of ELVN options activity at a glance. Use our scanner to monitor the ELVN option chain in real time and filter for the trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For ELVN stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where ELVN options are being actively traded, and where they are not.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
| CALLs | PUTs | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prob. OTM % | Open Interest | Volume | Extrinsic Value | Intrinsic Value | Bid | Ask | Strike | Moneyness % | Bid | Ask | Intrinsic Value | Extrinsic Value | Volume | Open Interest | Prob. OTM % |
| 4.51 | 1 | 0 | 0.37 | 11.53 | 9.80 | 14.00 | 35.00 | -24.78 | — | 3.40 | 0.00 | 3.40 | 0 | 22 | 95.49 |
| 19.19 | 36 | 0 | 0.77 | 6.53 | 6.90 | 7.70 | 40.00 | -14.03 | — | 2.70 | 0.00 | 2.70 | 0 | 6 | 80.81 |
| 44.25 | 113 | 0 | 2.39 | 1.53 | 2.15 | 5.70 | 45.00 | -3.29 | 0.20 | 4.20 | 0.00 | 2.20 | 6 | 8 | 55.75 |
| 69.33 | 44 | 0 | 1.03 | 0.00 | 0.05 | 2.00 | 50.00 | +7.46 | 3.10 | 7.00 | 3.47 | 1.58 | 0 | 2 | 30.67 |
| 86.28 | 35 | 2 | 2.00 | 0.00 | — | 2.00 | 55.00 | +18.20 | 7.00 | 10.90 | 8.47 | 0.48 | 0 | 5 | 13.72 |
As of Nov 20, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank12.70% Low
- Market cap (M$)3,424
- 52 weeks high-25.34%
- 52 weeks low214.82%
- Analyst recommendationStrong Buy
1.13 - Target price$73.85
58.71% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-05
- P/E—
- Future P/E—
- EPS (ttm)-1.70
- EPS growth next 5 years-12.26%
As of Nov 20, 2026